Prospective study of statin use and risk of Parkinson disease

Archives of Neurology

Volumn 69, Issue 3, 2012, Pages 380-384

  Gao, Xiang ^a,b   Simon, Kelly C ^a   Schwarzschild, Michael A ^c   Ascherio, Alberto ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IBUPROFEN;

ADULT; AGE; AGE DISTRIBUTION; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIETARY INTAKE; DRUG USE; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SMOKING; UNITED STATES;

ADULT; AGE FACTORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; IBUPROFEN; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; SMOKING;

EID: 84858611748     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.1060     Document Type: Article

References (34)

1. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother. 2008;42(9):1208-1215.
2. Becker C, Meier CR. Statins and the risk of Parkinson disease: an update on the controversy. Expert Opin Drug Saf. 2009;8(3):261-271.
3. Wang Q, Yan J, Chen X, et al. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol. 2011;230(1):27-34.
4. Wood WG, Eckert GP, Igbavboa U, Müller WE. Statins and neuroprotection: a prescription to move the field forward. Ann N Y Acad Sci. 2010;1199:69-76.
5. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18(suppl):S137-S144.
6. De Pinieux G, Chariot P, Ammi-Saïd M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol. 1996;42(3):333-337.
7. Shults CW, Oakes D, Kieburtz K, et al; Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59(10):1541-1550.
8. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.
9. Ritz B, Manthripragada AD, Qian L, et al. Statin use and Parkinson's disease in Denmark. Mov Disord. 2010;25(9):1210-1216.
10. Siegel D, Lopez J, Meier J. Use of cholesterol-lowering medications in the United States from 1991 to 1997. Am J Med. 2000;108(6):496-499. (Pubitemid 30214202)
11. Feskanich D, Rimm EB, Giovannucci EL, et al. Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire. J Am Diet Assoc. 1993;93(7):790-796. (Pubitemid 23260170)
12. Ascherio A, Zhang SM, Hernán MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol. 2001; 50(1):56-63.
13. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Genetic determinants of hair color and Parkinson's disease risk. Ann Neurol. 2009;65(1):76-82.
14. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology. 2009;73(16):1286-1291.
15. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003; 24(2):197-211. (Pubitemid 36007810)
16. Hernández-Presa MA, Martín-Ventura JL, Ortego M, et al. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis. 2002;160(1):49-58. (Pubitemid 34082716)
17. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res. 2002; 45(2):147-154. (Pubitemid 35425654)
18. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Statin use and the risk of Parkinson disease. Neurology. 2008;70(16, pt 2):1418-1422. (Pubitemid 351521934)
19. Huang X, Chen H, Miller WC, et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord. 2007;22(3):377-381. (Pubitemid 46569693)
20. de Lau LM, Stricker BH, Breteler MM. Serum cholesterol, use of lipid-lowering drugs, and risk of Parkinson disease. Mov Disord. 2007;22(13):1985. (Pubitemid 350134222)
21. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007;5:20.
22. Samii A, Carleton BC, Etminan M. Statin use and the risk of Parkinson disease: a nested case control study. J Clin Neurosci. 2008;15(11):1272-1273.
23. Becker C, Jick SS, Meier CR. Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. Drug Saf. 2008;31(5):399-407. (Pubitemid 351563732)
24. Ogata N, Fujimori S, Oka Y, Kaneko K. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids. 2010;29(4-6):321-324.
25. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol. 2007;166(5):561-567. (Pubitemid 47283643)
26. Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A. Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol. 2008;167(7):831-838. (Pubitemid 351451751)
27. Ascherio A, LeWitt PA, Xu K, et al Parkinson Study Group DATATOP Investigators. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009;66(12):1460-1468.
28. Schwarzschild MA, Schwid SR, Marek K, et al Parkinson Study Group PRECEPT Investigators. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65(6):716-723. (Pubitemid 351831449)
29. National Institute for Health Care Management Research and Educational Foundation. Prescription drug expenditures in 2000. http://www.nihcm.org/pdf/ spending2000.pdf. Accessed Nov 8, 2010.
30. Koob AO, Ubhi K, Paulsson JF, et al. Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol. 2010;221(2):267-274.
31. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology. 2011;76(10):863-869.
32. Hu G. Total cholesterol and the risk of Parkinson's disease: a review for some new findings. Parkinsons Dis. 2010;2010:836962.
33. Human JA, Ubbink JB, Jerling JJ, et al. The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clin Chim Acta. 1997;263(1):67-77. (Pubitemid 27285929)
34. Müller T, Kuhn W, Pöhlau D, Przuntek H. Parkinsonism unmasked by lovastatin. Ann Neurol. 1995;37(5):685-686.